This FDA label expansion significantly increases the total addressable market for VYVGART in gMG. Monitor upcoming catalysts including ADAPT OCULUS (ocular MG) and ADAPT Jr (pediatric) readouts, which could further expand the label. Watch for competitive dynamics from UCB's Rystiggo and JNJ's nipocalimab.
Price Chart
Executive Summary
FDA approved label expansion for VYVGART and VYVGART Hytrulo to treat all serotypes of generalized myasthenia gravis (gMG), including anti-MuSK, anti-LRP4, and triple-seronegative patients. The expansion is based on positive Phase 3 ADAPT SERON data and increases the addressable gMG patient population by approximately 20%.
Key Facts
- FDA approved label expansion for VYVGART and VYVGART Hytrulo to cover all gMG serotypes (anti-AChR, anti-MuSK, anti-LRP4, triple seronegative).
- Approval based on Phase 3 ADAPT SERON study (n=119) showing significant improvement in MG-ADL score at week 4 (p=0.0068).
- Expands addressable gMG patients by ~20% (non-AChR-Ab positive patients).
- VYVGART now has the broadest MG label to date.
Financial Impact
Expands addressable market by ~20% in gMG; VYVGART's current annual revenue is ~$2B, expansion could add several hundred million in peak sales.
Risk Factors
- Competition from other FcRn inhibitors (UCB, JNJ).
- Potential pricing/reimbursement pressures.
- Safety signals in broader real-world use.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291372 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Institutional Cluster | $984.04 $995.77 | ▲ +1.19% | ▲ +1.69% | $918.23 (−6.69%) |
Aug 17, 2026 6w ago | 6-K | $987.84 $1,011.11 | ▲ +2.36% | ▲ +3.55% | $918.23 (−7.05%) |
Aug 6, 2026 8w ago | Press Release | $875.30 $856.94 | ▼ −2.10% | ▼ −3.31% | $918.23 (+4.91%) |
Jul 27, 2026 9w ago | 6-K | $888.82 $853.82 | ▼ −3.94% | ▼ −5.01% | $918.23 (+3.31%) |
Jul 27, 2026 9w ago | Press Release | $888.82 $853.82 | ▼ −3.94% | ▼ −5.01% | $918.23 (+3.31%) |
Jul 23, 2026 10w ago | Press Release | $924.60 $872.58 | ▼ −5.63% | ▼ −6.10% | $918.23 (−0.69%) |
Jul 16, 2026 11w ago | Press Release | $857.97 $924.60 | ▲ +7.77% | ▲ +9.44% | $918.23 (+7.02%) |
Jun 23, 2026 14w ago | 6-K | $853.40 $912.46 | ▲ +6.92% | ▲ +5.91% | $918.23 (+7.60%) |
Jun 3, 2026 17w ago | 6-K | $813.14 $862.18 | ▲ +6.03% | ▲ +9.85% | $918.23 (+12.92%) |
May 8, 2026 20w ago | Press Release | $813.28 $776.26 | ▼ −4.55% | ▼ −4.47% | $918.23 (+12.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access